CAMBRIDGE, Mass. & PHILADELPHIA, Pa. – May 6, 2026 – Nava Therapeutics, a biotechnology company developing a new class of genetic medicines through precision RNA delivery, today announced that Ali Nahvi, Ph.D., Chief Technology Officer, will present preclinical data on the company’s lipid nanoparticle (LNP) delivery platform at TIDES USA 2026: Oligonucleotide and Peptide Therapeutics, taking place May 11-14, 2026, at the Hynes Convention Center in Boston.
Discovery
Learnings
- auto_storiesStories
- categoryAreas
- helpFAQ
- forumConversations
- descriptionPapers
- mailNewsletters
- video_libraryVideos
- timelineTimeline
Guidance
- codeTechnology of APIs
- business_centerBusiness of APIs
- campaignEvangelism of APIs
- gavelGovernance of APIs
- historyHistory of APIs
- account_balancePolitics of APIs
Toolbox
- domainProviders
- apiAPIs
- cloudSolutions
- buildTools
- verifiedStandards
- gavelRegulations
- horizontal_ruleHeaders
- layersOverlays
- extensionExtensions
- schemaSchema
- policyPolicies
- ruleRules